Vimizim launch price annual 2014 $380,000?

Yes. At its U.S. launch in 2014, Vimizim (elosulfase alfa) had a list price of about $380,000 per year per patient.

Notes:
- Dosing for Morquio A (MPS IVA) is 2 mg/kg IV once weekly.
- Actual prices paid can differ by country, payer negotiations, discounts, and patient assistance programs; the list price may not reflect net prices.

Would you like a brief comparison with other enzyme replacement therapies or more details on pricing factors?